參考文獻 |
Ambrosetti, D.C., Basilico, C., and Dailey, L. (1997). Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol Cell Biol 17, 6321-6329.
Angelucci, A., Valentini, A., Millimaggi, D., Gravina, G.L., Miano, R., Dolo, V., Vicentini, C., Bologna, M., Federici, G., and Bernardini, S. (2006). Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 17, 1141-1150.
Avilion, A.A., Nicolis, S.K., Pevny, L.H., Perez, L., Vivian, N., and Lovell-Badge, R. (2003). Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17, 126-140.
Bernadt, C.T., Nowling, T., and Rizzino, A. (2004). Transcription factor Sox-2 inhibits co-activator stimulated transcription. Mol Reprod Dev 69, 260-267.
Boer, B., Bernadt, C.T., Desler, M., Wilder, P.J., Kopp, J.L., and Rizzino, A. (2006). Differential activity of the FGF-4 enhancer in F9 and P19 embryonal carcinoma cells. J Cell Physiol 208, 97-108.
Boer, B., Kopp, J., Mallanna, S., Desler, M., Chakravarthy, H., Wilder, P.J., Bernadt, C., and Rizzino, A. (2007). Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res 35, 1773-1786.
Bradbury, C.A., Khanim, F.L., Hayden, R., Bunce, C.M., White, D.A., Drayson, M.T., Craddock, C., and Turner, B.M. (2005). Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19, 1751-1759.
Brehm, A., Ohbo, K., and Scholer, H. (1997). The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain. Mol Cell Biol 17, 154-162.
Carey, B.W., Markoulaki, S., Hanna, J., Saha, K., Gao, Q., Mitalipova, M., and Jaenisch, R. (2009). Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 106, 157-162.
Cavallaro, M., Mariani, J., Lancini, C., Latorre, E., Caccia, R., Gullo, F., Valotta, M., DeBiasi, S., Spinardi, L., Ronchi, A., et al. (2008). Impaired generation of mature neurons by neural stem cells from hypomorphic Sox2 mutants. Development 135, 541-557.
Cervoni, N., Detich, N., Seo, S.B., Chakravarti, D., and Szyf, M. (2002). The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 277, 25026-25031.
Chen, G., Huang, L.D., Jiang, Y.M., and Manji, H.K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72, 1327-1330.
Chen, L., and Khillan, J.S. (2010). A novel signaling by vitamin A/retinol promotes self renewal of mouse embryonic stem cells by activating PI3K/Akt signaling pathway via insulin-like growth factor-1 receptor. Stem Cells 28, 57-63.
Chen, L., and Liu, L. (2009). Current progress and prospects of induced pluripotent stem cells. Sci China C Life Sci 52, 622-636.
Chen, M., Zhang, H., Wu, J., Xu, L., Xu, D., Sun, J., He, Y., Zhou, X., Wang, Z., Wu, L., et al. (2012). Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway. Biomaterials 33, 5514-5523.
Chen, Y., Pan, R.L., Zhang, X.L., Shao, J.Z., Xiang, L.X., Dong, X.J., and Zhang, G.R. (2009). Induction of hepatic differentiation of mouse bone marrow stromal stem cells by the histone deacetylase inhibitor VPA. J Cell Mol Med 13, 2582-2592.
Cheng, Y.C., Lin, H., Huang, M.J., Chow, J.M., Lin, S., and Liu, H.E. (2007). Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 31, 1403-1411.
Chew, J.L., Loh, Y.H., Zhang, W., Chen, X., Tam, W.L., Yeap, L.S., Li, P., Ang, Y.S., Lim, B., Robson, P., et al. (2005). Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 25, 6031-6046.
Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005). Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309, 1369-1373.
Feng, B., Jiang, J., Kraus, P., Ng, J.H., Heng, J.C., Chan, Y.S., Yaw, L.P., Zhang, W., Loh, Y.H., Han, J., et al. (2009). Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol 11, 197-203.
Ferri, A.L., Cavallaro, M., Braida, D., Di Cristofano, A., Canta, A., Vezzani, A., Ottolenghi, S., Pandolfi, P.P., Sala, M., DeBiasi, S., et al. (2004). Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 131, 3805-3819.
Fuhrmann, G., Chung, A.C., Jackson, K.J., Hummelke, G., Baniahmad, A., Sutter, J., Sylvester, I., Scholer, H.R., and Cooney, A.J. (2001). Mouse germline restriction of Oct4 expression by germ cell nuclear factor. Dev Cell 1, 377-387.
Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969-6978.
Grosschedl, R., Giese, K., and Pagel, J. (1994). HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 10, 94-100.
Guo, Y., Costa, R., Ramsey, H., Starnes, T., Vance, G., Robertson, K., Kelley, M., Reinbold, R., Scholer, H., and Hromas, R. (2002). The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci U S A 99, 3663-3667.
Gupta, P., Ho, P.C., Huq, M.M., Ha, S.G., Park, S.W., Khan, A.A., Tsai, N.P., and Wei, L.N. (2008). Retinoic acid-stimulated sequential phosphorylation, PML recruitment, and SUMOylation of nuclear receptor TR2 to suppress Oct4 expression. Proc Natl Acad Sci U S A 105, 11424-11429.
Gurpur, P.B., Liu, J., Burkin, D.J., and Kaufman, S.J. (2009). Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 174, 999-1008.
He, L., Liu, H., and Tang, L. (2012). SWI/SNF chromatin remodeling complex: a new cofactor in reprogramming. Stem Cell Rev 8, 128-136.
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., and Melton, D.A. (2008). Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26, 1269-1275.
Jung, G.A., Yoon, J.Y., Moon, B.S., Yang, D.H., Kim, H.Y., Lee, S.H., Bryja, V., Arenas, E., and Choi, K.Y. (2008). Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol 9, 66.
Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-775.
Kamachi, Y., Uchikawa, M., and Kondoh, H. (2000). Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 16, 182-187.
Kopp, J.L., Ormsbee, B.D., Desler, M., and Rizzino, A. (2008). Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 26, 903-911.
Lampen, A., Siehler, S., Ellerbeck, U., Gottlicher, M., and Nau, H. (1999). New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol 160, 238-249.
Lan, M.J., Yuan, P., Chen, G., and Manji, H.K. (2008). Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate. J Mol Neurosci 35, 225-234.
Lang, K.C., Lin, I.H., Teng, H.F., Huang, Y.C., Li, C.L., Tang, K.T., and Chen, S.L. (2009). Simultaneous overexpression of Oct4 and Nanog abrogates terminal myogenesis. Am J Physiol Cell Physiol 297, C43-54.
Lebreton, S., Carraz, G., Behriel, H., and Meunier, H. (1964). [Pharmacodynamic Properties of 2,2-Dipropylacetic Acid. Iii]. Therapie 19, 457-467.
Lee, M.Y., Lim, H.W., Lee, S.H., and Han, H.J. (2009). Smad, PI3K/Akt, and Wnt-dependent signaling pathways are involved in BMP-4-induced ESC self-renewal. Stem Cells 27, 1858-1868.
Lunke, S., and El-Osta, A. (2009). The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J Neurochem 109, 1557-1569.
Marchion, D.C., Bicaku, E., Daud, A.I., Sullivan, D.M., and Munster, P.N. (2005). Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65, 3815-3822.
Martirosyan, A., Leonard, S., Shi, X., Griffith, B., Gannett, P., and Strobl, J. (2006). Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Exp Ther 317, 546-552.
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9, 493-495.
McElroy, S.L., Keck, P.E., Jr., Pope, H.G., Jr., and Hudson, J.I. (1989). Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 50 Suppl, 23-29.
Mesdjian, E., Ciesielski, L., Valli, M., Bruguerolle, B., Jadot, G., Bouyard, P., and Mandel, P. (1982). Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat. Prog Neuropsychopharmacol Biol Psychiatry 6, 223-233.
Meyer, N., and Penn, L.Z. (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8, 976-990.
Mora, A., Sabio, G., Alonso, J.C., Soler, G., and Centeno, F. (2002). Different dependence of lithium and valproate on PI3K/PKB pathway. Bipolar Disord 4, 195-200.
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., and Yamanaka, S. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26, 101-106.
Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Scholer, H., and Smith, A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-391.
Nishimoto, M., Fukushima, A., Okuda, A., and Muramatsu, M. (1999). The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol Cell Biol 19, 5453-5465.
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-376.
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317.
Palamarchuk, A., Efanov, A., Maximov, V., Aqeilan, R.I., Croce, C.M., and Pekarsky, Y. (2005). Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res 65, 4515-4519.
Pan, G.J., Chang, Z.Y., Scholer, H.R., and Pei, D. (2002). Stem cell pluripotency and transcription factor Oct4. Cell Res 12, 321-329.
Pan, T., Li, X., Xie, W., Jankovic, J., and Le, W. (2005). Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 579, 6716-6720.
Peltier, J., Conway, A., Keung, A.J., and Schaffer, D.V. (2011). Akt increases sox2 expression in adult hippocampal neural progenitor cells, but increased sox2 does not promote proliferation. Stem Cells Dev 20, 1153-1161.
Pesce, M., and Scholer, H.R. (2000). Oct-4: control of totipotency and germline determination. Mol Reprod Dev 55, 452-457.
Pevny, L., and Placzek, M. (2005). SOX genes and neural progenitor identity. Curr Opin Neurobiol 15, 7-13.
Pikarsky, E., Sharir, H., Ben-Shushan, E., and Bergman, Y. (1994). Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region. Mol Cell Biol 14, 1026-1038.
Ralston, A., and Rossant, J. (2005). Genetic regulation of stem cell origins in the mouse embryo. Clin Genet 68, 106-112.
Rizzino, A. (2009). Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med 1, 228-236.
Rosato, R.R., Almenara, J.A., and Grant, S. (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63, 3637-3645.
Rowland, B.D., and Peeper, D.S. (2006). KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6, 11-23.
Scholer, H.R., Ruppert, S., Suzuki, N., Chowdhury, K., and Gruss, P. (1990). New type of POU domain in germ line-specific protein Oct-4. Nature 344, 435-439.
Schoorlemmer, J., van Puijenbroek, A., van Den Eijnden, M., Jonk, L., Pals, C., and Kruijer, W. (1994). Characterization of a negative retinoic acid response element in the murine Oct4 promoter. Mol Cell Biol 14, 1122-1136.
Shan, S.W., Tang, M.K., Chow, P.H., Maroto, M., Cai, D.Q., and Lee, K.K. (2007). Induction of growth arrest and polycomb gene expression by reversine allows C2C12 cells to be reprogrammed to various differentiated cell types. Proteomics 7, 4303-4316.
Smith, K.P., Luong, M.X., and Stein, G.S. (2009). Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol 220, 21-29.
Sommer, C.A., Stadtfeld, M., Murphy, G.J., Hochedlinger, K., Kotton, D.N., and Mostoslavsky, G. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543-549.
Stimson, L., Wood, V., Khan, O., Fotheringham, S., and La Thangue, N.B. (2009). HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20, 1293-1302.
Tada, M., Takahama, Y., Abe, K., Nakatsuji, N., and Tada, T. (2001). Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol 11, 1553-1558.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
Teramura, T., Takehara, T., Onodera, Y., Nakagawa, K., Hamanishi, C., and Fukuda, K. (2012). Mechanical stimulation of cyclic tensile strain induces reduction of pluripotent related gene expressions via activation of Rho/ROCK and subsequent decreasing of AKT phosphorylation in human induced pluripotent stem cells. Biochem Biophys Res Commun 417, 836-841.
Terme, J.M., Lhermitte, L., Asnafi, V., and Jalinot, P. (2009). TGF-beta induces degradation of TAL1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation. Blood 113, 6695-6698.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147.
Tomioka, M., Nishimoto, M., Miyagi, S., Katayanagi, T., Fukui, N., Niwa, H., Muramatsu, M., and Okuda, A. (2002). Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 30, 3202-3213.
Wegner, M. (1999). From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 27, 1409-1420.
Wegner, M., and Stolt, C.C. (2005). From stem cells to neurons and glia: a Soxist’’s view of neural development. Trends Neurosci 28, 583-588.
Werling, U., Siehler, S., Litfin, M., Nau, H., and Gottlicher, M. (2001). Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol 59, 1269-1276.
Wernig, M., Meissner, A., Cassady, J.P., and Jaenisch, R. (2008). c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10-12.
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable offspring derived from fetal and adult mammalian cells. Nature 385, 810-813.
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770.
Yang, H.M., Do, H.J., Kim, D.K., Park, J.K., Chang, W.K., Chung, H.M., Choi, S.Y., and Kim, J.H. (2007). Transcriptional regulation of human Oct4 by steroidogenic factor-1. J Cell Biochem 101, 1198-1209.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920.
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4, 381-384.
Ziauddin, M.F., Yeow, W.S., Maxhimer, J.B., Baras, A., Chua, A., Reddy, R.M., Tsai, W., Cole, G.W., Jr., Schrump, D.S., and Nguyen, D.M. (2006). Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8, 446-457.
|